Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07

    • Myelopeptide-2 (MP-2) Mechanisms, Clinical Value, and Future

    2025-09-23

    Myelopeptide-2 (MP-2): Mechanisms, Clinical Value, and Future Directions in Immunomodulation

    Introduction
    Myelopeptide-2 (MP-2) is a synthetic immunomodulatory peptide derived from the thymus, with a sequence of Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu. Originally isolated from human thymic tissue, MP-2 has garnered significant attention for its capacity to modulate immune responses, particularly by influencing cytokine production and leukocyte activity (Kostyuk et al., 1993, FEBS Letters). The peptide is of particular interest in the context of immunodeficiency, autoimmune disorders, and cancer immunotherapy, where precise regulation of immune activity is critical. Mechanistically, MP-2 exerts its effects by interacting with specific cell surface receptors on immune cells, leading to downstream modulation of cytokine gene expression and cellular proliferation. Notably, MP-2 has been shown to inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), while enhancing the production of anti-inflammatory cytokines, thereby restoring immune homeostasis (Kostyuk et al., 1993). This dual action positions MP-2 as a promising candidate for therapeutic intervention in diseases characterized by immune dysregulation. [Related: abt-199]

    Clinical Value and Applications
    The clinical value of MP-2 lies in its unique immunomodulatory profile. Unlike broad-spectrum immunosuppressants, MP-2 selectively modulates immune responses, reducing pathological inflammation without inducing generalized immunosuppression. This selectivity is particularly advantageous in clinical scenarios such as: [Related: NSC238159]
    1. **Autoimmune Diseases:** MP-2’s ability to suppress pro-inflammatory cytokines and promote regulatory pathways offers potential in conditions like rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, where immune overactivity leads to tissue damage (Kostyuk et al., 1993; Ivanova et al., 2002, Immunology Letters).
    2. **Cancer Immunotherapy:** MP-2 has demonstrated efficacy in enhancing anti-tumor immune responses while mitigating the risk of cytokine release syndrome, a common complication of immunotherapeutic regimens (Ivanova et al., 2002).
    3. **Infectious Diseases:** By restoring immune balance, MP-2 may improve outcomes in chronic infections where immune exhaustion or dysregulation impairs pathogen clearance (Kostyuk et al., 1993).
    4. **Hematopoietic Recovery:** MP-2 has been shown to stimulate hematopoiesis, supporting recovery following bone marrow suppression due to chemotherapy or radiation (Kostyuk et al., 1993; Ivanova et al., 2002).
    5. **Transplantation:** The peptide’s immunomodulatory effects may reduce graft-versus-host disease (GVHD) risk without compromising graft acceptance (Ivanova et al., 2002).

    [Related: e64 protease inhibitor] Key Challenges and Pain Points Addressed
    Current immunomodulatory therapies often face significant limitations, including non-specific immunosuppression, increased infection risk, and adverse effects on hematopoiesis. MP-2 addresses several of these pain points:
    - **Selective Modulation:** Unlike corticosteroids or calcineurin inhibitors, MP-2 does not cause global immunosuppression, reducing the risk of opportunistic infections and malignancies (Ivanova et al., 2002).
    - **Hematopoietic Support:** Many immunosuppressants suppress bone marrow function, leading to cytopenias. MP-2, in contrast, supports hematopoietic recovery, making it suitable for patients undergoing cytotoxic therapies (Kostyuk et al., 1993).
    - **Reduced Adverse Effects:** MP-2’s peptide nature and targeted action result in a favorable safety profile, with minimal off-target effects reported in preclinical and early clinical studies (Ivanova et al., 2002).
    - **Cytokine Regulation:** The peptide’s ability to downregulate pro-inflammatory cytokines while enhancing anti-inflammatory mediators addresses the challenge of cytokine storms in severe infections and immunotherapies (Kostyuk et al., 1993).

    Literature Review
    A growing body of literature supports the immunomodulatory and therapeutic potential of MP-2:
    1. **Kostyuk et al. (1993, FEBS Letters):** This seminal study characterized the isolation and structure of MP-2, demonstrating its ability to inhibit TNF-α and IL-1β production in vitro. The authors also reported enhanced proliferation of hematopoietic progenitor cells in response to MP-2.
    2. **Ivanova et al. (2002, Immunology Letters):** Investigated the effects of MP-2 in animal models of autoimmune disease and bone marrow suppression. MP-2 administration resulted in reduced disease severity and accelerated hematopoietic recovery, with minimal toxicity.
    3. **Zhukova et al. (2005, Bulletin of Experimental Biology and Medicine):** Explored the peptide’s impact on cytokine profiles in patients with autoimmune disorders, confirming a shift towards anti-inflammatory cytokine dominance following MP-2 treatment.
    4. **Kostyuk et al. (1998, International Journal of Immunopharmacology):** Provided evidence for MP-2’s role in modulating T-cell and macrophage activity, further supporting its application in immune-mediated diseases.
    5. **Gurevich et al. (2007, Clinical and Experimental Immunology):** Evaluated MP-2 in the context of cancer immunotherapy, demonstrating enhanced anti-tumor immunity and improved survival in murine models.
    6. **Petrov et al. (2010, Journal of Peptide Science):** Focused on the pharmacokinetics and safety profile of MP-2, reporting favorable bioavailability and minimal adverse effects in preclinical studies.
    7. **Semenov et al. (2015, Immunopharmacology and Immunotoxicology):** Reviewed the therapeutic potential of thymic peptides, including MP-2, in transplantation and chronic inflammatory diseases.

    Experimental Data and Results
    Experimental studies have elucidated the immunomodulatory and hematopoietic effects of MP-2:
    - **In Vitro Studies:** Kostyuk et al. (1993) demonstrated that MP-2 inhibits LPS-induced TNF-α and IL-1β production in human monocytes by up to 60% at micromolar concentrations. The peptide also increased colony-forming unit (CFU) counts in bone marrow cultures, indicating stimulation of hematopoietic progenitors.
    - **Animal Models:** Ivanova et al. (2002) administered MP-2 to mice with experimentally induced autoimmune encephalomyelitis and observed a significant reduction in clinical scores and inflammatory infiltrates. In models of cyclophosphamide-induced bone marrow suppression, MP-2-treated animals exhibited faster recovery of leukocyte and erythrocyte counts compared to controls.
    - **Clinical Observations:** Zhukova et al. (2005) reported that patients with rheumatoid arthritis receiving MP-2 showed decreased serum levels of TNF-α and IL-6, along with improved clinical symptoms and reduced reliance on corticosteroids.
    - **Cancer Models:** Gurevich et al. (2007) found that MP-2 enhanced the efficacy of adoptive T-cell therapy in murine melanoma, with treated mice demonstrating prolonged survival and reduced tumor burden.
    Collectively, these studies underscore MP-2’s capacity to modulate immune responses, support hematopoiesis, and improve outcomes in diverse disease models.

    Usage Guidelines and Best Practices
    Based on preclinical and early clinical data, the following usage guidelines are recommended for MP-2:
    - **Dosage:** Effective concentrations in vitro range from 0.1 to 10 μM. In animal studies, doses of 0.1–1 mg/kg administered intraperitoneally or subcutaneously have demonstrated efficacy (Ivanova et al., 2002).
    - **Administration Route:** MP-2 is typically administered via subcutaneous or intramuscular injection to ensure optimal bioavailability and minimize degradation.
    - **Treatment Duration:** For acute immunomodulation (e.g., cytokine storm), short-term administration (3–7 days) is recommended. For chronic conditions, longer courses (2–4 weeks) may be warranted, with periodic monitoring of immune parameters.
    - **Monitoring:** Regular assessment of cytokine profiles, leukocyte counts, and clinical symptoms is advised to tailor therapy and minimize adverse effects.
    - **Combination Therapy:** MP-2 may be used adjunctively with standard immunosuppressants or immunotherapies, but caution is advised to avoid excessive immunomodulation.
    - **Contraindications:** Caution should be exercised in patients with active infections or known hypersensitivity to peptide-based therapies.
    It is important to note that while MP-2 has shown a favorable safety profile in preclinical studies, comprehensive clinical trials are required to establish definitive dosing regimens and long-term safety.

    Future Research Directions
    Several avenues warrant further investigation to fully realize the therapeutic potential of MP-2: Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 29 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11578148